Thermo Fisher Scientific recently settled with the family of Henrietta Lacks, who had her cells taken without consent over 70 years ago. These cervical cancer cells, known as HeLa cells, have profoundly impacted scientific discoveries due to their unique ability to thrive in lab environments. The cells eventually found their way to companies like Thermo Fisher, sparking ethical discussions.
Legal experts and researchers are discussing the implications of this settlement for the scientific community and future legal actions. Caprice Roberts from Louisiana State University Law highlights the precedent this case sets, igniting conversations about the origins of scientific resources.
Rebecca Skloot’s book “The Immortal Life of Henrietta Lacks” brought attention to the unethical use of these cells. Institutions, including the US National Institutes of Health, engaged with the Lacks family, leading to initiatives promoting transparency and respect.
The versatility of HeLa cells has fueled research, yet the family hadn’t been compensated for their contributions. The Thermo Fisher settlement is groundbreaking, possibly prompting similar legal actions against companies profiting from such cells.
While the unique circumstances of Lacks’s case might not extend to all tissue use situations, it underscores the broader ethical considerations. Experts emphasize patients’ rights to decide the use of their biological samples and the challenges of establishing consent systems for broader research.
As companies profit from biological specimens, the Thermo Fisher settlement emphasizes the importance of ethically sourcing samples, regardless of whether they collected them.
